All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 133 of 206 pages ‹ First < 131 132 133 134 135 > Last ›
HSL712
Editorial .
Prescription for Confusion
THE NEW YORK TIMES 2004 Dec 28
HSL713
O'Connor , A .
Vioxx. Celebrex. Now Aleve. What's a Patient to Think?
The New York Times 2004 Dec 28
HSL703
Editorial /, S .
Take drugs off the market
USA Today 2004 Dec 27
HSL704
Rost P.
Big Pharma's Dirty Little Secret
The LA Times 2004 Dec 26
HSL705
Krasner , J .
Stents sold despite high failure rates: BSX held off recall amid alarming data
The Boston Globe 2004 Dec 26
HSL707
Editoral .
FDA warnings
The Boston Globe 2004 Dec 26
HSL708
Hensley , S .
New risks put old drugs in spotlight
The Wall Street Journal 2004 Dec 26
HSL714
Goldstein , S .
Bill would shield some drug firms from punitive damages: A provision in medical malpractice legislation would protect manufacturers that meet FDA standards.
Philadelphia Inquirer 2004 Dec 26
HSL774
Hudson P.
What's in it for me?
The Hearld Sun 2004 Dec 26
HSL700
O'Gilfoil Healy, P .
Spitzer, in a Shift, Will Yield Inquiries to U.S. Regulators
The New York Times 2004 Dec 25
HSL701
Henderson D.
Calls are mounting for revamp of FDA
The Boston Globe 2004 Dec 25
HSL702
Siegel M.
Put the Brakes on the Wonder Drug Express
The Washington Post 2004 Dec 25
HSL1637
Raphael MF, Bouts AH, Sukhai RN.
[Sweets from the pharmaceutical industry reason to suspect intoxication with quetiapine] .
Ned Tijdschr Geneeskd 2004 Dec 25;148:(52):2583-4
HSL706
Kerber , R .
22% of medical device follow-up studies left undone
The Boston Globe 2004 Dec 24
HSL163
Silverman E.
Choosing their words carefully
NJ Star-Ledger 2004 Dec 23
HSL696
Editorial .
The Sick NIH
The LA Times 2004 Dec 23
HSL709
Medicare to Test Ways to End Disparities Amid Evidence That Closing Treatment Gaps Saves More Lives Than R&D
Washington Health Policy Week in Review 2004 Dec 23
HSL716
Reuters .
Aleve Warnings May Be Exaggerated
The Wall Street Journal 2004 Dec 23
HSL162
Willman D.
The National Institutes of Health: Public Servant or Private Marketer?
The Los Angeles Times 2004 Dec 22
HSL697
Willman , D .
$508,050 From Pfizer, but No 'Outside Positions to Note'
The LA Times 2004 Dec 22
HSL698
William D.
Case study| Dr. Lance A. Liotta and Emanuel F. 'Chip' Petricoin III: Firm's Research Stalls as Cancer Experts Work for Rival
The LA Times 2004 Dec 22
HSL699
William D.
Case Study| Dr. Harvey G. Klein: Public Pays for Blood Expert's Advice, and So Do Firms
The LA Times 2004 Dec 22
HSL715
Heavey , S .
FDA Says AstraZeneca Crestor Ad Is Misleading
Reuters 2004 Dec 22
HSL146
Maher S.
Heart monitor on arthritis drug
The Australian 2004 Dec 21
HSL156
Harris G.
A 4th Painkiller Is Tied to Increased Heart Risk
The New York Times 2004 Dec 21
HSL160
Goozner M.
Op-Ed Contributor: Overdosed and Oversold
New York Times 2004 Dec 21
HSL161
Rowland C.
Drug makers revamping clinical-trial system: New test strategies focus on weeding out duds sooner
The Boston Globe 2004 Dec 21
HSL144
Getting a Toehold for Research Comparing Medical Treatments
Washington Health Policy Week in Review 2004 Dec 20
HSL148
Saunders M.
Arthritis drug wins backing
The Australian 2004 Dec 20
HSL150
Pfizer to stop advertising painkiller: report
ABC News Online 2004 Dec 20
HSL710
Grassley Plays Up Role as Government Watchdog, Focuses on FDA
Washington Health Policy Week in Review 2004 Dec 20
HSL773
Harvey M, Frenkel J.
PBS fix-it plan to save billions
The Hearld Sun 2004 Dec 20
HSL722
Meier B .
Medicine Fueled by Marketing Intensified Trouble for Pain Pills
The New York Times 2004 Dec 19
HSL1
Mansfield P.
Accepting what we can learn from advertising's mirror of desire.
BMJ 2004 Dec 18;329:(7480):1487-8
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15604193
HSL139
New Doubts About Celebrex
THE NEW YORK TIMES 2004 Dec 18
HSL159
Pugh T, Borenstein S.
American Consumers Suffering as More New Drugs Debut in US, Analysis Shows
Knight-Ridder 2004 Dec 18
HSL739
Berenson , A .
Pricey Drug Trials Turn Up Few New Blockbusters
The New York Times 2004 Dec 18
HSL1638
Offerhaus L.
[The pharmaceutical industry in scandal: Mercury or Aesculapius?]
Ned Tijdschr Geneeskd 2004 Dec 18;148:(51):2554-6
HSL2037
Scott T, Stanford N, Thompson DR.
Killing me softly: myth in pharmaceutical advertising.
BMJ 2004 Dec 18;329:(7480):1484-7
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15604192
HSL129
Pfizer's statement on Celebrex: Firm finds one of two studies showed patients on Celebrex had an increased risk of heart attacks.
CNN 2004 Dec 17
HSL130
Hensley .
Pfizer Says Study Shows Heart Risk From Celebrex: Shares Sink 11% on News
Wall Street Journal 2004 Dec 17
HSL142
Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex: Dosing in Long-Term Cancer Studies Suspended Due to Increased Cardiovascular Risk in One Study; Preliminary Analysis of Second Long-Term Cancer Study Shows No Increased Cardi
Pfizer.com 2004 Dec 17
HSL1197
Mandatory Reporting of Adverse Drug Reactions: An important first step
Canadian Women's Health Network 2004 Dec 17
HSL1989
Young T.
Medication Errors Involving Reminyl* and Amaryl
Janssen-Ortho Inc. & Aventis Pharma Inc.. 2004 Dec 17
HSL71
Sarasohn J.
Tauzin to Head Drug Trade Group
The Washington Post 2004 Dec 16
HSL76
Kaufman M.
Many FDA Scientists Had Drug Concerns, 2002 Survey Shows
The Washington Post 2004 Dec 16
HSL80
Bias seen in U.S. drug study reporting
United Press International 2004 Dec 16
HSL141
Prescription Drugs: About One-Fifth of FDA Scientists Felt Pressured To Approve Medications, Despite Safety Concerns, Survey Shows
Kaiser Daily Health Policy Report 2004 Dec 16
HSL723
Lueck , S .
Tauzin Is Named Top Lobbyist For Pharmaceuticals Industry: Departing Congressman Is Former Head of Panel That Oversaw Drug Sector
THE WALL STREET JOURNAL 2004 Dec 16
HSL771
Generics See Evergreening as Red
Corrs In Brief 2004 Dec 16
HSL65
Meier B.
Flawed Device Places F.D.A. Under Scrutiny
The New York Times 2004 Dec 15
HSL70
Safety issue concerns Grassley: The senator sees his probe of the drug approval process as vital to consumers' well-being.
REGISTER WASHINGTON BUREAU 2004 Dec 15
HSL74
Weiss S.
Tauzin Raised Six-Figure Sum from Drug Makers: The New Head of PhRMA Enjoyed the Financial Support of Pharmaceutical Manufacturers While in Congress
Capital Eye 2004 Dec 15
HSL78
Solomon J, Herschaft R.
Woman Died During AIDS Study
The Associated Press 2004 Dec 15
HSL61
Zuger A.
We Love Them. We Hate Them. We Take Them.
The New York Times 2004 Dec 14
HSL58
Herper M.
Face Of The Year: David Graham
2004 Dec 13
HSL60
U.S. Officials Knew of AIDS Drug Risks: Top U.S. Officials Warned of Concerns Before AIDS Drug Sent to Africa
The Associated Press 2004 Dec 13
HSL81
Norton A.
Ads for body-imaging health screens may mislead
Reuters 2004 Dec 13
HSL56
Starr D.
The Cuban Biotech Revolution Embargo or no, Castro's socialist paradise has quietly become a pharmaceutical powerhouse. (They're still working on the capitalism thing.)
Wired Magazine 2004 Dec 12
HSL63
Johnston L.
My wife killed herself because of Prozac, so why is it still being prescribed?
SUNDAY EXPRESS 2004 Dec 12
HSL772
NUPGE hails victory in battle to end drug patent abuse
NUPGE 2004 Dec 12
HSL55
Rowland C.
High-profile ruling near for Maine, drug firms
The Boston Globe 2004 Dec 11
HSL49
Rabin R.
Pill study was wrong: Report touting health benefits from drug's use was flawed, didn't get OK from Women's Health Initiative
Newsday 2004 Dec 10
HSL52
Prozac is risky for children too
BBC News 2004 Dec 10
HSL20051
Arthur I
Cut back drug promotions
Medical Observer 2004 Dec 1019
HSL47
Shipman report demands GMC reform
BBC News 2004 Dec 9
HSL48
Mangan K.
Medical Association Calls for End to Confidentiality Demands by Research Sponsors
The Chronicle of Higher Education 2004 Dec 9
HSL50
FDA Warns Heart-Bypass Patients Shouldn't Take Painkiller Bextra
The Wall Street Journal 2004 Dec 9
HSL51
Drug Maker Withheld Paxil Study Data: ABC News Uncovers Documents Unknown to Regulators and Many Doctors
ABC News 2004 Dec 9
HSL53
Carroll J.
Extreme Disease Deficit
San Francisco Chronicle 2004 Dec 8
HSL778
Metherell M.
New deadline for medicine costs pledge
Sydney Morning Heral 2004 Dec 8
HSL22
Boseley S.
Antidepressant pills 'too readily prescribed': Medicines regulator decides there is no evidence drugs cause increased self harm but inquiry criticised for not seeing full trial data
2004 Dec 7
HSL23
Vedantam S.
British Officials Advise Less Use of Antidepressants
The Washington Post 2004 Dec 7
HSL11543
Angell M.
Excess in the pharmaceutical industry.
CMAJ 2004 Dec 7;171:(12):1451-3
http://www.cmaj.ca/cgi/content/full/171/12/1451
HSL20
Harris G.
At F.D.A., Strong Drug Ties and Less Monitoring
The New York Times 2004 Dec 6
HSL21
Boseley S.
Antidepressants to be ruled safe: Watchdog criticised for today's announcement
The Guardian 2004 Dec 6
HSL24
Hale V.
Creating More Paths to Hope
Newsweek 2004 Dec 6
HSL45
McCoy K.
Drugmaker rebuffed call to monitor users
USA TODAY 2004 Dec 6
HSL46
Britain overdoses on anti-depressants
The Daily Mail 2004 Dec 6
HSL355
Jureidini J, Tonkin A, Mansfield PR.
TADS study raises concerns.
BMJ 2004 Dec 4;329:(7478):1343-4
http://bmj.bmjjournals.com/cgi/content/full/329/7478/1343-d
HSL67
Hirschler B.
Britain May Tighten Rules on Antidepressant Drugs
Reuters 2004 Dec 3
HSL19852
Limprecht E
RACGP fundraiser ethics questioned
Australian Doctor 2004 Dec 3
http://www.australiandoctor.com.au/news/racgp-fundraiser-ethics-questioned
HSL1639
Finucane TE, Boult CE.
Association of funding and findings of pharmaceutical research at a meeting of a medical professional society.
Am J Med 2004 Dec 1;117:(11):842-5
http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(04)00583-2
HSL1890
Fitzgerald MA.
Appropriate antibiotic prescribing. Guidance for the use of drug samples
Adv Nurse Pract. 2004 Dec 01;12:(12):18-22
HSL5304
Muijrers PE, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA.
Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners.
Eur J Clin Pharmacol 2004 Dec 01;60:(10):739-46
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3055&uid=15517226&db=PubMed&url=http://dx.doi.org/10.1007/s00228-004-0821-5
HSL5333
Fontanarosa PB, Rennie D, DeAngelis CD.
Postmarketing surveillance--lack of vigilance, lack of trust.
JAMA 2004 Dec 1;292:(21):2647-50
http://jama.ama-assn.org/cgi/content/full/292/21/2647
HSL5347
Lichtenberg P, Heresco-Levy U, Nitzan U.
The ethics of the placebo in clinical practice.
J Med Ethics 2004 Dec 01;30:(6):551-4
http://jmp.oxfordjournals.org/content/31/1/65.abstract
HSL353
Light DW, Lexchin J.
Will lower drug prices jeopardize drug research? A policy fact sheet
Am J Bioeth 2004 Winter;4:(1):1-4
http://bioethics.net/journal/j_articles.php?aid=61
HSL1615
Douglas KM, Sutton RM.
Right about others, wrong about ourselves? Actual and perceived self-other differences in resistance to persuasion
Br J Soc Psychol 2004 Dec;43:(Pt 4):585-603
http://www.ingentaconnect.com/content/bpsoc/bjsp/2004/00000043/00000004/art00007?token=005c10cc4e7247444f6d6222346b62687633502b333e3541333c4a2f246c6a38574b675423783c77eefc266e7e60
HSL1641
Waack KE, Ernst ME, Graber MA.
Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction.
Ann Pharmacother 2004 Dec;38:(12):2029-34
http://www.theannals.com/cgi/content/full/38/12/2029
HSL1642
Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG.
Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.
Med Care 2004 Dec;42:(12):1176-85
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7079&volume=42&issue=12&spage=1176
HSL4893
Caplan A, Elliott C.
Is it ethical to use enhancement technologies to make us better than well?
PLoS Med 2004 Dec;1:(3):e52
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15630464
HSL4895
Turner EH.
A taxpayer-funded clinical trials registry and results database.
PLoS Med 2004 Dec;1:(3):e60
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15562322
HSL19388
Mizik N, Jacobson R
Are physicians 'easy marks'? quantifying the effects of detailing and sampling on new prescriptions
Management Science 2004 Dec;50:(12):
http://portal.acm.org/citation.cfm?id=1045853
HSL20131
CHSRF
Myth: Direct-to-consumer advertising is educational for patients
Mythbusters 2004 Dec;
http://jhsrp.rsmjournals.com/content/11/3/189.citation
HSL719
Meier B .
The Academic Connection: Contracts Keep Drug Research Out of Reach
The New York Times 2004 Nov 29
HSL1643
Food and Drug Administration, HHS.
Drug labeling; sodium labeling for over-the-counter drugs.
Federal Register 2004 Nov 29;69:(228):
http://a257.g.akamaitech.net/7/257/2422/06jun20041800/edocket.access.gpo.gov/2004/pdf/04-26269.pdf
HSL7452
Carey J, Barrett A, Cropper CM.
Lessons From The Vioxx Fiasco : What drugmakers, the FDA, doctors, and patients need to do
Business Week 2004 Nov 29
http://www.businessweek.com/magazine/content/04_48/b3910055_mz011.htm?chan=search
HSL7982
Zarembo A.
Bayer Held Back on Drug Dangers
Los Angeles Times 2004 Nov 23A12
http://pqasb.pqarchiver.com/latimes/access/741574781.html?dids=741574781:741574781&FMT=ABS&FMTS=ABS:FT&type=current&date=Nov+23%2C+2004&author=Alan+Zarembo&pub=Los+Angeles+Times&edition=&startpage=A.12&desc=The+Nation
HSL19829
Lexchin J, Mintzes B
Transparency in drug regulation: Mirage or oasis?
CMAJ 2004 Nov 23;171:(11):1363-5
http://www.cmaj.ca/content/171/11/1363
Page 133 of 206 pages ‹ First < 131 132 133 134 135 > Last ›
